{
  "run_id": "RUN_20260204_234342_996d5a3920e1",
  "timestamp": "2026-02-05T03:33:23.732568",
  "document": "Adie-Syndrome.pdf",
  "document_path": "/Users/frederictetard/Projects/ese/gold_data/NLP4RARE/train/Adie-Syndrome.pdf",
  "pipeline_version": "0.8",
  "total_candidates": 1,
  "total_validated": 1,
  "total_rejected": 0,
  "total_investigational": 0,
  "drugs": [
    {
      "matched_text": "pilocarpine",
      "preferred_name": "pilocarpine",
      "brand_name": "OCUSERT PILO-20",
      "compound_id": null,
      "confidence": 0.7,
      "is_investigational": false,
      "drug_class": null,
      "mechanism": null,
      "development_phase": null,
      "sponsor": null,
      "conditions": [],
      "nct_id": null,
      "dosage_form": "INSERT, EXTENDED RELEASE",
      "route": "OPHTHALMIC",
      "marketing_status": "Discontinued",
      "codes": {
        "rxcui": null,
        "mesh": "D010862",
        "ndc": null,
        "drugbank": null,
        "unii": null
      },
      "all_identifiers": [
        {
          "system": "FDA_NDA",
          "code": "NDA017431",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D010862",
          "display": "Pilocarpine"
        }
      ],
      "context": "ot be necessary. Glasses may be prescribed to correct blurred vision; sunglasses can help individuals with sensitivity to light. Therapy using dilute pilocarpine may improve poor depth perception and relieve glare in some patients. The loss of deep tendon reflexes is permanent.",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_fda_approved_drugs.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Pilocarpine",
      "enrichment_source": "pubtator3"
    }
  ]
}